Companies /Healthcare
Idexx Laboratories Inc
NASDAQ: IDXX Diagnostics & Research
$702.25
▼ $1.98 (−0.28%) today
Markets open · 3:04pm ET

IDEXX Laboratories (IDXX) Q3 2026 Earnings

Reported Nov 2, 2026, 6:30am ET · SEC source
$4.01
Beat +7.91%
EPS · est. $3.72 GAAP

Q3 EPS included a $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and a $0.04 per share benefit from year-over-year currency changes, while absorbing acquisition impacts including transaction-related costs; company-reported comparable EPS was $3.96.

$1.2B
Beat +1.83%
Revenue · est. $1.2B
8 quarters
Consecutive EPS beats

How Did IDXX Stock React to Q3 2026 Earnings?

+21.85%
Day of report
+0.06%
Next session
+5.21%
One week

Did IDXX Beat Earnings? Q3 2026 Results

Yes. IDEXX Laboratories reported Q3 2026 earnings of $4.01 a share on Nov 2, 2026, beating the $3.72 consensus estimate by 7.9%. Revenue was $1.2B against a $1.2B estimate.

IDEXX Laboratories delivered a strong third quarter of 2026, posting GAAP EPS of $4.01 against a consensus estimate of $3.72, a beat of 7.91% that extended the company's streak of exceeding consensus EPS estimates to seven consecutive quarters. Revenue of $1.21 billion rose 9.9% year over year, clearing the $1.19 billion consensus by 1.83%, as CAG Diagnostics recurring revenue, the company's core growth engine, climbed 11% both reported and organically. The result was powered by a 14% to 15% surge in VetLab consumables tied to an 11% expansion of the premium instrument installed base, alongside strong international momentum and U.S. volume growth the company said exceeded sector trends. GAAP EPS of $4.01 included a $0.03 per-share non-operating gain on an equity investment, $0.01 in share-based compensation tax benefits, and a $0.04 currency tailwind. Looking ahead, management raised full-year 2026 EPS guidance to $14.96 to $15.16 and lifted revenue guidance to $4.74 billion to $4.77 billion, reflecting continued organic momentum and the addition of CoVet, its recently acquired AI clinical assistant for veterinary teams.

Key Takeaways
  • CAG Diagnostics recurring revenue grew 11% reported and organic, with International up 13% reported/14% organic and U.S. up 10%
  • IDEXX VetLab consumables grew 14% reported and 15% organic on net new customers, 11% premium instrument installed base expansion, and new product utilization
  • Reference lab revenue grew 10% on testing volume, new customers and price realization
  • Over 1,900 inVue Dx placements in the quarter, installed base nearly 11,000
  • Strong diagnostic imaging installations led by ImageVue DR50 Plus
  • Gross margin up 110 bps to 62.9% on volume gains, productivity initiatives and net price realization
  • Operating margin up 100 bps to 33.1%

“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy.”

IDEXX Laboratories CEO, on the earnings call

What Is IDEXX Laboratories's Outlook?

IDEXX raised its 2026 revenue guidance to $4,741M–$4,767M (prior $4,700M–$4,745M), up $32M at midpoint including $5M from CoVet. - Reported revenue growth: 10.1%–10.8%; organic growth: 9.3%–10.0%. - CAG Diagnostics recurring revenue growth: 11.0%–11.7% reported, 10.3%–11.0% organic. - Operating margin: lowered to 32.1%–32.3% (50–70 bps expansion) to reflect acquisition-related impacts. - EPS: raised to $14.96–$15.16 (prior $14.69–$14.94), or 14%–16% reported and 15%–16% comparable growth. - Other assumptions: net interest expense ~$32M, effective tax rate ~20.5%, ~2% reduction in average shares outstanding, and capex ~$160M. - Cash flow: operating cash flow at 110%–120% of net income and free cash flow at 95%–100% of net income. - Currency: FX expected to add ~0.7% to revenue growth and ~$0.25 to EPS.

IDXX YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$400.0M$800.0M$1.2B$1.1B$1.2BRevenue$683.3M$764.3MGross Profit$354.8M$402.3MOperating Income$274.6M$317.1MNet Income
$0$400.0M$800.0M$1.2BRevenueGross ProfitOperating IncomeNet Income
IDXX income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $1.2B $1.1B +9.9%
Gross Profit $764.3M $683.3M +11.9%
Operating Income $402.3M $354.8M +13.4%
Net Income $317.1M $274.6M +15.5%

IDXX Revenue by Segment

Companion Animal Group$1.1B+10.2%
CAG Diagnostics Recurring Revenue
IDEXX VetLab Consumables$443.2M+14.3%
Reference Laboratory Diagnostic and Consulting Services$399.1M+10.0%
Rapid Assay Products$89.1M+0.6%
Veterinary Software, Services and Diagnostic Imaging Systems$97.1M+10.6%
Water$58.8M+8.4%
CAG Diagnostics Capital Instruments$51.5M+0.0%

IDXX Revenue by Geography

United States$766.6M+8.7%
Rest of World$447.7M+11.9%

When Does IDEXX Laboratories Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.